特异性突变可预测复发/难治性弥漫大 B 细胞淋巴瘤

IF 2.1 Q3 HEMATOLOGY
Journal of Blood Medicine Pub Date : 2024-09-10 eCollection Date: 2024-01-01 DOI:10.2147/JBM.S471639
Jing Wang, Lei Tian, Weilong Zhang, Shuhan Tang, Wei Zhao, Yu Guo, Chaoling Wu, Yuansheng Lin, Xiaoyan Ke, Hongmei Jing
{"title":"特异性突变可预测复发/难治性弥漫大 B 细胞淋巴瘤","authors":"Jing Wang, Lei Tian, Weilong Zhang, Shuhan Tang, Wei Zhao, Yu Guo, Chaoling Wu, Yuansheng Lin, Xiaoyan Ke, Hongmei Jing","doi":"10.2147/JBM.S471639","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The application of rituximab has significantly enhanced the overall survival rates in patients with diffuse large B-cell lymphoma (DLBCL). Regrettably, a significant number of patients still progress to relapse/refractory DLBCL (rrDLBCL).</p><p><strong>Methods: </strong>Herein, we employed targeted sequencing of 55 genes to investigate if gene mutations could predict the progression to rrDLBCL. Additionally, we compared the mutation profiles at the time of DLBCL diagnosis with those found in rrDLBCL cases.</p><p><strong>Results: </strong>Our findings highlighted significantly elevated mutation frequencies of <i>TP53, MEF2B</i> and <i>CD58</i> in diagnostic biopsies from patients who progressed to relapse or refractory disease, with CD58 mutations exclusively observed in the rrDLBCL group. In assessing the predictive power of mutation profiles for treatment responses in primary DLBCL patients, we found that the frequency of <i>CARD11</i> mutations was substantially higher in non-response group as compared with those who responded to immunochemotherapy. In addition, we revealed mutations in <i>HIST2H2AB, BCL2, NRXN3, FOXO1, HIST1H1C, LYN</i> and <i>TBL1XR1</i> genes were only detected in initial diagnostic biopsies, mutations in the EBF1 gene were solely detected in the rrDLBCL patients.</p><p><strong>Conclusion: </strong>Collectively, this study elucidates some of the genetic mechanisms contributing to the progression of rrDLBCL and suggests that the presence of <i>CD58</i> mutations might serve as a powerful predictive marker for relapse/refractory outcomes in primary DLBCL patients.</p>","PeriodicalId":15166,"journal":{"name":"Journal of Blood Medicine","volume":"15 ","pages":"407-419"},"PeriodicalIF":2.1000,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11401521/pdf/","citationCount":"0","resultStr":"{\"title\":\"Specific Mutation Predict Relapse/Refractory Diffuse Large B-Cell Lymphoma.\",\"authors\":\"Jing Wang, Lei Tian, Weilong Zhang, Shuhan Tang, Wei Zhao, Yu Guo, Chaoling Wu, Yuansheng Lin, Xiaoyan Ke, Hongmei Jing\",\"doi\":\"10.2147/JBM.S471639\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The application of rituximab has significantly enhanced the overall survival rates in patients with diffuse large B-cell lymphoma (DLBCL). Regrettably, a significant number of patients still progress to relapse/refractory DLBCL (rrDLBCL).</p><p><strong>Methods: </strong>Herein, we employed targeted sequencing of 55 genes to investigate if gene mutations could predict the progression to rrDLBCL. Additionally, we compared the mutation profiles at the time of DLBCL diagnosis with those found in rrDLBCL cases.</p><p><strong>Results: </strong>Our findings highlighted significantly elevated mutation frequencies of <i>TP53, MEF2B</i> and <i>CD58</i> in diagnostic biopsies from patients who progressed to relapse or refractory disease, with CD58 mutations exclusively observed in the rrDLBCL group. In assessing the predictive power of mutation profiles for treatment responses in primary DLBCL patients, we found that the frequency of <i>CARD11</i> mutations was substantially higher in non-response group as compared with those who responded to immunochemotherapy. In addition, we revealed mutations in <i>HIST2H2AB, BCL2, NRXN3, FOXO1, HIST1H1C, LYN</i> and <i>TBL1XR1</i> genes were only detected in initial diagnostic biopsies, mutations in the EBF1 gene were solely detected in the rrDLBCL patients.</p><p><strong>Conclusion: </strong>Collectively, this study elucidates some of the genetic mechanisms contributing to the progression of rrDLBCL and suggests that the presence of <i>CD58</i> mutations might serve as a powerful predictive marker for relapse/refractory outcomes in primary DLBCL patients.</p>\",\"PeriodicalId\":15166,\"journal\":{\"name\":\"Journal of Blood Medicine\",\"volume\":\"15 \",\"pages\":\"407-419\"},\"PeriodicalIF\":2.1000,\"publicationDate\":\"2024-09-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11401521/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Blood Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2147/JBM.S471639\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Blood Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2147/JBM.S471639","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:利妥昔单抗的应用大大提高了弥漫大B细胞淋巴瘤(DLBCL)患者的总生存率。方法:在此,我们对 55 个基因进行了靶向测序,以研究基因突变能否预测 rrDLBCL 的进展。此外,我们还将 DLBCL 诊断时的基因突变情况与 rrDLBCL 病例中发现的基因突变情况进行了比较:结果:我们的研究结果表明,在复发或难治性疾病患者的诊断活检组织中,TP53、MEF2B和CD58的突变频率明显升高,其中CD58突变仅见于rrDLBCL组。在评估突变图谱对原发性DLBCL患者治疗反应的预测能力时,我们发现与对免疫化疗有反应的患者相比,无反应组中CARD11突变的频率要高得多。此外,我们还发现HIST2H2AB、BCL2、NRXN3、FOXO1、HIST1H1C、LYN和TBL1XR1基因的突变仅在初始诊断活检中被检测到,EBF1基因的突变仅在rrDLBCL患者中被检测到:总之,本研究阐明了导致rrDLBCL进展的一些遗传机制,并提示CD58基因突变的存在可作为原发性DLBCL患者复发/难治结果的有力预测标志。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Specific Mutation Predict Relapse/Refractory Diffuse Large B-Cell Lymphoma.

Background: The application of rituximab has significantly enhanced the overall survival rates in patients with diffuse large B-cell lymphoma (DLBCL). Regrettably, a significant number of patients still progress to relapse/refractory DLBCL (rrDLBCL).

Methods: Herein, we employed targeted sequencing of 55 genes to investigate if gene mutations could predict the progression to rrDLBCL. Additionally, we compared the mutation profiles at the time of DLBCL diagnosis with those found in rrDLBCL cases.

Results: Our findings highlighted significantly elevated mutation frequencies of TP53, MEF2B and CD58 in diagnostic biopsies from patients who progressed to relapse or refractory disease, with CD58 mutations exclusively observed in the rrDLBCL group. In assessing the predictive power of mutation profiles for treatment responses in primary DLBCL patients, we found that the frequency of CARD11 mutations was substantially higher in non-response group as compared with those who responded to immunochemotherapy. In addition, we revealed mutations in HIST2H2AB, BCL2, NRXN3, FOXO1, HIST1H1C, LYN and TBL1XR1 genes were only detected in initial diagnostic biopsies, mutations in the EBF1 gene were solely detected in the rrDLBCL patients.

Conclusion: Collectively, this study elucidates some of the genetic mechanisms contributing to the progression of rrDLBCL and suggests that the presence of CD58 mutations might serve as a powerful predictive marker for relapse/refractory outcomes in primary DLBCL patients.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
3.50
自引率
0.00%
发文量
94
审稿时长
16 weeks
期刊介绍: The Journal of Blood Medicine is an international, peer-reviewed, open access, online journal publishing laboratory, experimental and clinical aspects of all topics pertaining to blood based medicine including but not limited to: Transfusion Medicine (blood components, stem cell transplantation, apheresis, gene based therapeutics), Blood collection, Donor issues, Transmittable diseases, and Blood banking logistics, Immunohematology, Artificial and alternative blood based therapeutics, Hematology including disorders/pathology related to leukocytes/immunology, red cells, platelets and hemostasis, Biotechnology/nanotechnology of blood related medicine, Legal aspects of blood medicine, Historical perspectives. Original research, short reports, reviews, case reports and commentaries are invited.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信